🎉 M&A multiples are live!
Check it out!

Clinuvel Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Clinuvel Pharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Julphar.

Clinuvel Pharma Overview

About Clinuvel Pharma

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.


Founded

1999

HQ

Australia
Employees

16

Website

clinuvel.com

Financials

LTM Revenue $61.7M

LTM EBITDA $31.7M

EV

$240M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Clinuvel Pharma Financials

Clinuvel Pharma has a last 12-month revenue of $61.7M and a last 12-month EBITDA of $31.7M.

In the most recent fiscal year, Clinuvel Pharma achieved revenue of $55.8M and an EBITDA of $35.6M.

Clinuvel Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Clinuvel Pharma valuation multiples based on analyst estimates

Clinuvel Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $49.5M $55.8M XXX XXX XXX
Gross Profit $34.9M $44.0M XXX XXX XXX
Gross Margin 71% 79% XXX XXX XXX
EBITDA $31.3M $35.6M XXX XXX XXX
EBITDA Margin 63% 64% XXX XXX XXX
Net Profit $13.2M $19.4M XXX XXX XXX
Net Margin 27% 35% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Clinuvel Pharma Stock Performance

As of March 14, 2025, Clinuvel Pharma's stock price is AUD 12 (or $7).

Clinuvel Pharma has current market cap of AUD 577M (or $365M), and EV of AUD 380M (or $240M).

See Clinuvel Pharma trading valuation data

Clinuvel Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$240M $365M XXX XXX XXX XXX $0.47

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Clinuvel Pharma Valuation Multiples

As of March 14, 2025, Clinuvel Pharma has market cap of $365M and EV of $240M.

Clinuvel Pharma's trades at 3.9x LTM EV/Revenue multiple, and 7.6x LTM EBITDA.

Analysts estimate Clinuvel Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Clinuvel Pharma and 10K+ public comps

Clinuvel Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $240M XXX XXX XXX
EV/Revenue 4.1x XXX XXX XXX
EV/EBITDA 7.0x XXX XXX XXX
P/E 15.5x XXX XXX XXX
P/E/Growth 1.8x XXX XXX XXX
EV/FCF 10.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Clinuvel Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Clinuvel Pharma Valuation Multiples

Clinuvel Pharma's NTM/LTM revenue growth is 6%

Clinuvel Pharma's revenue per employee for the last fiscal year averaged $3.5M, while opex per employee averaged $1.2M for the same period.

Over next 12 months, Clinuvel Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Clinuvel Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Clinuvel Pharma and other 10K+ public comps

Clinuvel Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 13% XXX XXX XXX XXX
EBITDA Margin 58% XXX XXX XXX XXX
EBITDA Growth 14% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 64% XXX XXX XXX XXX
Revenue per Employee $3.5M XXX XXX XXX XXX
Opex per Employee $1.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 28% XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 34% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Clinuvel Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Clinuvel Pharma M&A and Investment Activity

Clinuvel Pharma acquired  XXX companies to date.

Last acquisition by Clinuvel Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Clinuvel Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Clinuvel Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Clinuvel Pharma

When was Clinuvel Pharma founded? Clinuvel Pharma was founded in 1999.
Where is Clinuvel Pharma headquartered? Clinuvel Pharma is headquartered in Australia.
How many employees does Clinuvel Pharma have? As of today, Clinuvel Pharma has 16 employees.
Who is the CEO of Clinuvel Pharma? Clinuvel Pharma's CEO is Dr. Philippe J. Wolgen, M.B.A.,M.D..
Is Clinuvel Pharma publicy listed? Yes, Clinuvel Pharma is a public company listed on ASX.
What is the stock symbol of Clinuvel Pharma? Clinuvel Pharma trades under CUV ticker.
When did Clinuvel Pharma go public? Clinuvel Pharma went public in 2001.
Who are competitors of Clinuvel Pharma? Similar companies to Clinuvel Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Clinuvel Pharma? Clinuvel Pharma's current market cap is $365M
What is the current revenue of Clinuvel Pharma? Clinuvel Pharma's last 12-month revenue is $61.7M.
What is the current EBITDA of Clinuvel Pharma? Clinuvel Pharma's last 12-month EBITDA is $31.7M.
What is the current EV/Revenue multiple of Clinuvel Pharma? Current revenue multiple of Clinuvel Pharma is 3.9x.
What is the current EV/EBITDA multiple of Clinuvel Pharma? Current EBITDA multiple of Clinuvel Pharma is 7.6x.
What is the current revenue growth of Clinuvel Pharma? Clinuvel Pharma revenue growth between 2023 and 2024 was 13%.
Is Clinuvel Pharma profitable? Yes, Clinuvel Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.